Affimed (AFMD) Reports Q3 Loss of EUR0.14/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Affimed (AFMD) Reports Q3 Loss of EUR0.14/sh

Affimed (AFMD) Reports Preclinical Data on Mechanism of Action of two Innate Cell Engagers, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

November 12, 2021 7:02 AM EST

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three posters with preclinical data of its innate cell engagers (ICE®) are presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The data highlight Affimeds preclinical initiatives to further elucidate the mechanisms of action for its lead ICE® candidates AFM13 and AFM24, providing evidence that both ICE® molecules increased the number of NK cells which functioned as serial killers against cancer as well as the... More